Once a Silicon Valley pioneer in consumer genetic testing, 23andMe is now at the center of a high-stakes legal and financial drama. After filing for bankruptcy in March 2025, the company has drawn intense interest in its massive DNA data repository, leading to a fresh bidding war that underscores the growing value of genetic information in medicine and research.
The latest twist came as Anne Wojcicki, 23andMe’s co-founder and former CEO, offered $305 million in partnership with the TTAM Research Institute, a California-based medical research organization. This offer exceeds the previous $256 million bid from pharmaceutical giant Regeneron, who had initially been declared the winner of the first auction held last month.
The updated bid not only raised the stakes financially, but also resolved a series of legal disputes surrounding the first auction process. Wojcicki had objected to the original outcome, claiming that the company’s procedures unfairly favored Regeneron by prematurely closing the bidding.
Courtroom Compromise and Auction Rules
The case was heard in federal bankruptcy court in St. Louis, where U.S. Bankruptcy Judge Brian Walsh played a crucial role in revising the auction structure to ensure fairness and transparency. Initially, 23andMe’s proposed rules included controversial conditions such as a $10 million breakup fee and restricted bid increments which Walsh said could hinder competitive bidding and were potentially “inefficient.”
Following a heated courtroom debate, the parties agreed on a new bidding process. Under the updated rules:
- Wojcicki and TTAM will place an opening bid of $305 million.
- Regeneron can respond with a counteroffer of at least $315 million.
- Wojcicki’s group will then have a chance to bid again.
- Regeneron will retain the right to make the final offer.
Though Wojcicki’s legal team criticized the “last-look” rule as favoring Regeneron, they ultimately supported the new framework, calling it a fairer process that allows both parties to compete meaningfully.
DNA Data as a Strategic Asset
At the heart of this bidding war lies 23andMe’s genetic database, which contains DNA information from over 15 million customers who submitted saliva samples for health and ancestry analysis. Despite the company’s financial troubles, this vast dataset is considered a goldmine by both pharmaceutical companies and research institutions seeking personalized medical breakthroughs.
Regeneron, known for its work in drug development, sees the data as a powerful tool for precision medicine and clinical insights. Meanwhile, Wojcicki’s camp aims to keep the company’s mission intact by preserving its research-first philosophy and commitment to consumer privacy.
The sale of genetic data has naturally sparked public concern. Many customers and advocacy groups worry that their most personal information could be misused, especially given the company’s history of privacy breaches including a 2023 data breach that allowed hackers access to sensitive data.
Both bidders have stated their commitment to upholding 23andMe’s privacy policy, which permits customers to delete their personal data upon request. However, skepticism remains high, and lawmakers have been watching the process closely.
A Company in Decline
Founded in 2006 with lofty ambitions to democratize access to genetic information, 23andMe was once a darling of the biotech world. It provided ancestry breakdowns and health risk reports to consumers for a fee and later expanded into drug development partnerships and telehealth through its Lemonaid Health subsidiary.
But the company’s financial model proved unsustainable. With only about 550,000 active subscribers, 23andMe struggled to cover operational costs and failed to turn a profit. Revenue from consumer testing has declined sharply, even as competition in the genetic testing space has intensified.
Lemonaid Health will now be wound down, and is not part of the sale process, 23andMe confirmed in a recent statement.
While the new auction is a step toward resolving ownership of the company’s most valuable asset, 23andMe still faces significant legal hurdles. The company is currently trying to settle a class-action lawsuit related to the 2023 data breach and must also satisfy claims from unsecured creditors and shareholders.
Lawyers representing these groups said during the recent hearing that they support the new auction structure, viewing it as a more transparent path toward maximizing the value of the company’s assets.
The second and final auction is scheduled to take place later this month, and it promises to be a pivotal moment in the fate of 23andMe. Whether the company lands in the hands of a pharmaceutical powerhouse like Regeneron or returns to the stewardship of its former founder and a research-oriented institute could shape not only the future of the brand but the ethical standards surrounding consumer DNA data ownership.
For now, all eyes remain on the courtroom in Missouri, where financial, legal, and scientific interests are converging in one of the most closely watched bankruptcy battles in biotech history.
